CSI Market
Sign In | Register

Oncosec Medical Incorporated (ONCS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ONCS Annual Cash Flow →
The data below summarizes Oncosec Medical Incorporated's cash flow activity from Jan 31 2022 to Jan 31 2023, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jan 31 2023)
6 Months 		(Oct 31 2022) (Jul 31 2022) (Apr 30 2022) (Jan 31 2022)
Operating Activities
Income-14.92
Depreciation & amortization0.12
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.59
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total-0.07
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Fair Value Gain Loss Of Derivative Liabilities In Excess Of Proceeds-
Increase Decrease In Fair Value Of Unhedged Derivative Instruments-
Non Cash Interest Expense-
Stockbased Compensation Related To Stock Issuance Liability In Connection With Contractual Agreement-
Warrant Inducement Expense-
Stock Issued During Period Value Issued For Services Cash Flow Impact-
Modification Of Equity Award-
Operating Lease Right Of Use Asset Amortization-
Investment Income Net Amortization Of Discount And Premium-
Operating Lease Right Of Use Asset Amortization Expense0.20
Increase Decrease In Operating Lease Liability-0.22
Deferred Offering Costs Written Off0.04
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Employee Related Liabilities0.83
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.39
Increase (Decrease) in Workers Compensation Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.22
Other Working Capital0.08
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.01
Discontinued operations0.00
Net Cash flow from Operating Activities-12.74
Investing Activities
Capital Expenditures-0.02
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Available-for-sale Securities0.00
Payments for Tenant Improvements0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.11
Long-term debt - borrowings0.00
Long-term debt - repayments-0.56
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock3.50
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Common Stock And Warrants-
Other Payments For Asset Acquisition-
Proceeds From Issuance Of Common Stock Warrants Private Placements-
Proceeds From Warrant And Stock Option Exercises-
Repayment Of Tax Withholdings Paid On Equity Awards0.00
Tax Shares Sold To Pay For Tax Withholdings On Equity Awards0.00
Payments For Stock Options Cancellation-
Proceeds From Issuances Or Sale Of Equity0.00
Purchase Of Shares C G P And Sirtex Stock Purchase Agreements-
Proceeds From Copromotion Agreement-
Adjustments To Additional Paid In Capital Purchase Of Shares Under Cgp And Sirtex Stock Purchase Agreements-
Proceeds From Issuance Of Convertible Note Related Party2.00
Payment Of Financing And Offering Costs-0.67
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.16
Effect of exchange rate on cash flow-0.02
Discontinued operations0.00
Free Cash Flow-12.75
Total Cash Flow-8.62
4 historic quarters locked

Sign in to unlock the full Oncosec Medical Incorporated cash flow history.

Sign In Create Free Account

About Oncosec Medical Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-23-007478

Figures are derived from filed reports and may be restated. Historical data is subject to revision.